Alexander R Opotowsky1,2, Brittani Loukas3, Christina Ellervik4, Lilamarie E Moko3, Michael N Singh3,2, Elizabeth I Landzberg5, Eric B Rimm6,7, Michael J Landzberg3,2. 1. Department of Cardiology, Boston Children's Hospital, Boston, MA, USA alexander.opotowsky@cardio.chboston.org. 2. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 3. Department of Cardiology, Boston Children's Hospital, Boston, MA, USA. 4. Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA. 5. Columbia University Medical Center, New York City, NY, USA. 6. Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 7. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Adults with congenital heart disease (ACHD) comprise a growing, increasingly complex population. The Boston Adult Congenital Heart Disease Biobank is a program for the collection and storage of biospecimens to provide a sustainable resource for scientific biomarker investigation in ACHD. METHODS: We describe a protocol to collect, process, and store biospecimens for ACHD or associated diagnoses developed based on existing literature and consultation with cardiovascular biomarker epidemiologists. The protocol involves collecting urine and ∼48.5 mL of blood. A subset of the blood and urine undergoes immediate clinically relevant testing. The remaining biospecimens are processed soon after collection and stored at -80°C as aliquots of ethylenediaminetetraacetic acid (EDTA) and lithium heparin plasma, serum, red cell and buffy coat pellet, and urine supernatant. Including tubes with diverse anticoagulant and clot accelerator contents will enable flexible downstream use. Demographic and clinical data are entered into a database; data on biospecimen collection, processing, and storage are managed by an enterprise laboratory information management system. RESULTS: Since implementation in 2012, we have enrolled more than 650 unique participants (aged 18-80 years, 53.3% women); the Biobank contains over 11,000 biospecimen aliquots. The most common primary CHD diagnoses are single ventricle status-post Fontan procedure (18.8%), repaired tetralogy of Fallot with pulmonary stenosis or atresia (17.6%), and left-sided obstructive lesions (17.5%). CONCLUSIONS: We describe the design and implementation of biospecimen collection, handling, and storage protocols with multiple levels of quality assurance. These protocols are feasible and reflect the size and goals of the Boston ACHD Biobank.
BACKGROUND: Adults with congenital heart disease (ACHD) comprise a growing, increasingly complex population. The Boston Adult Congenital Heart Disease Biobank is a program for the collection and storage of biospecimens to provide a sustainable resource for scientific biomarker investigation in ACHD. METHODS: We describe a protocol to collect, process, and store biospecimens for ACHD or associated diagnoses developed based on existing literature and consultation with cardiovascular biomarker epidemiologists. The protocol involves collecting urine and ∼48.5 mL of blood. A subset of the blood and urine undergoes immediate clinically relevant testing. The remaining biospecimens are processed soon after collection and stored at -80°C as aliquots of ethylenediaminetetraacetic acid (EDTA) and lithium heparin plasma, serum, red cell and buffy coat pellet, and urine supernatant. Including tubes with diverse anticoagulant and clot accelerator contents will enable flexible downstream use. Demographic and clinical data are entered into a database; data on biospecimen collection, processing, and storage are managed by an enterprise laboratory information management system. RESULTS: Since implementation in 2012, we have enrolled more than 650 unique participants (aged 18-80 years, 53.3% women); the Biobank contains over 11,000 biospecimen aliquots. The most common primary CHD diagnoses are single ventricle status-post Fontan procedure (18.8%), repaired tetralogy of Fallot with pulmonary stenosis or atresia (17.6%), and left-sided obstructive lesions (17.5%). CONCLUSIONS: We describe the design and implementation of biospecimen collection, handling, and storage protocols with multiple levels of quality assurance. These protocols are feasible and reflect the size and goals of the Boston ACHD Biobank.
Authors: Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger Journal: JAMA Date: 2010-11-15 Impact factor: 56.272
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Paul Khairy; Jamil Aboul Hosn; Craig Broberg; Stephen Cook; Michael Earing; Deborah Gersony; Joseph Kay; Michael J Landzberg; Michelle J Nickolaus; Sasha Opotowsky; Anne Marie Valente; Carole Warnes; Gary Webb; Michelle Z Gurvitz Journal: Int J Cardiol Date: 2008-06-24 Impact factor: 4.164
Authors: Bonnie Ky; Benjamin French; Wayne C Levy; Nancy K Sweitzer; James C Fang; Alan H B Wu; Lee R Goldberg; Mariell Jessup; Thomas P Cappola Journal: Circ Heart Fail Date: 2012-02-23 Impact factor: 8.790
Authors: Alexander R Opotowsky; Omar K Siddiqi; Benjamin D'Souza; Gary D Webb; Susan M Fernandes; Michael J Landzberg Journal: Heart Date: 2011-10-11 Impact factor: 5.994
Authors: Alexander R Opotowsky; Fernando R Baraona; Finnian R Mc Causland; Brittani Loukas; Elizabeth Landzberg; Michael J Landzberg; Venkata Sabbisetti; Sushrut S Waikar Journal: Heart Date: 2016-09-26 Impact factor: 5.994
Authors: Konstantinos Dimopoulos; Gerhard-Paul Diller; Evdokia Koltsida; Antonia Pijuan-Domenech; Sofia A Papadopoulou; Sonya V Babu-Narayan; Tushar V Salukhe; Massimo F Piepoli; Philip A Poole-Wilson; Nicky Best; Darrel P Francis; Michael A Gatzoulis Journal: Circulation Date: 2008-04-28 Impact factor: 29.690
Authors: Alexander Lukasz; Gernot Beutel; Philipp Kümpers; Agnieszka Denecke; Mechthild Westhoff-Bleck; Bernhard Schieffer; Johann Bauersachs; Jan T Kielstein; Oktay Tutarel Journal: PLoS One Date: 2013-06-24 Impact factor: 3.240
Authors: Saurabh Rajpal; Laith Alshawabkeh; Nureddin Almaddah; Caroline M Joyce; Keri Shafer; Michelle Gurvitz; Sushrut S Waikar; Finnian R Mc Causland; Michael J Landzberg; Alexander R Opotowsky Journal: JAMA Cardiol Date: 2018-04-01 Impact factor: 14.676
Authors: Alexander R Opotowsky; Anne Marie Valente; Laith Alshawabkeh; Susan Cheng; Allison Bradley; Eric B Rimm; Michael J Landzberg Journal: Eur Heart J Date: 2018-09-07 Impact factor: 29.983
Authors: Matthew R Carazo; Meghan S Kolodziej; Elizabeth S DeWitt; Nadine A Kasparian; Jane W Newburger; Valeria E Duarte; Michael N Singh; Alexander R Opotowsky Journal: J Am Heart Assoc Date: 2020-04-28 Impact factor: 5.501
Authors: Adam M Lubert; Tarek Alsaied; Joseph J Palermo; Nadeem Anwar; Elaine M Urbina; Nicole M Brown; Craig Alexander; Hassan Almeneisi; Fred Wu; Andrew R Leventhal; Nael Aldweib; Michael Mendelson; Alexander R Opotowsky Journal: J Am Heart Assoc Date: 2021-03-31 Impact factor: 5.501
Authors: Cara L Lachtrupp; Anne Marie Valente; Michelle Gurvitz; Michael J Landzberg; Sarah B Brainard; Fred M Wu; Dorothy D Pearson; Keith Taillie; Alexander R Opotowsky Journal: J Am Heart Assoc Date: 2021-09-06 Impact factor: 5.501
Authors: Nael Aldweib; Eleni G Elia; Sarah B Brainard; Fred Wu; Lynn A Sleeper; Carla Rodriquez; Anne Marie Valente; Michael J Landzberg; Michael Singh; Mary Mullen; Alexander R Opotowsky Journal: Int J Cardiol Congenit Heart Dis Date: 2022-01-25
Authors: Laurie W Geenen; Alexander R Opotowsky; Cara Lachtrupp; Vivan J M Baggen; Sarah Brainard; Michael J Landzberg; David van Klaveren; Hester F Lingsma; Eric Boersma; Jolien W Roos-Hesselink Journal: Eur Heart J Qual Care Clin Outcomes Date: 2022-01-05